Rabbit Recombinant Monoclonal CD68 antibody. Suitable for Flow Cyt, mIHC, IHC-P and reacts with Human samples. Cited in 4 publications.
IgG
Rabbit
pH: 7.2 - 7.4
Preservative: 0.1% Sodium azide
Constituents: PBS, 1% BSA
Liquid
Monoclonal
Flow Cyt | mIHC | IHC-P | |
---|---|---|---|
Human | Tested | Tested | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/100 | Notes Incubate with primary antibody for 30 minutes at 4 °C. |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/300 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/100 | Notes Boil tissue section in citrate buffer, pH 6.0 for 10 minutes followed by cooling at room temperature for 20 minutes. Incubate with primary antibody for 10 minutes at room temperature. Recommend Hu species. IHC result showed staining on the macrophages in the human tissues such as tonsil, spleen and colon. The mouse and rat tissues showed no staining. |
Select an associated product type
Could play a role in phagocytic activities of tissue macrophages, both in intracellular lysosomal metabolism and extracellular cell-cell and cell-pathogen interactions. Binds to tissue- and organ-specific lectins or selectins, allowing homing of macrophage subsets to particular sites. Rapid recirculation of CD68 from endosomes and lysosomes to the plasma membrane may allow macrophages to crawl over selectin-bearing substrates or other cells.
Macrosialin, Gp110, CD68
Rabbit Recombinant Monoclonal CD68 antibody. Suitable for Flow Cyt, mIHC, IHC-P and reacts with Human samples. Cited in 4 publications.
Macrosialin, Gp110, CD68
IgG
Rabbit
pH: 7.2 - 7.4
Preservative: 0.1% Sodium azide
Constituents: PBS, 1% BSA
Liquid
Monoclonal
SP251
Affinity purification Protein A
Blue Ice
1-2 weeks
+4°C
-20°C
Upon delivery aliquot
Avoid freeze / thaw cycle
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
This product is FOR RESEARCH USE ONLY. For commercial use, please contact partnerships@abcam.com.
This supplementary information is collated from multiple sources and compiled automatically.
CD68 is a glycoprotein that functions as a scavenger receptor. It plays an important role in the regulation of cellular debris and apoptotic cell clearance. Researchers often refer to it as KP1 or macrosialin in the literature. CD68 with a molecular weight of approximately 110 kDa is highly expressed in macrophages and monocytes. The mucin-like structure of CD68 allows it to be heavily glycosylated which aids in its function. Researchers detect CD68 in tissues through methods like immunohistochemistry (IHC) immunofluorescence and CD68 staining and it is widely used as a macrophage marker in research.
CD68 facilitates functions associated with the innate immune response. It serves as an important part of macrophages which contribute to immune surveillance and tissue homeostasis. Though it primarily operates on its own in some contexts CD68 might assist in forming complexes with other receptors to modulate phagocytic activity. This target is significant in atherosclerotic plaque stability as macrophages engulf lipids and cell debris through processes facilitated by CD68.
CD68 is involved in pathways connected to inflammation and phagocytosis. The CD68 protein works closely with other scavenger receptors like CD36 to mediate uptake of oxidized low-density lipoproteins (oxLDL) in the lipid metabolism pathway. Additionally CD68 engagement can influence the toll-like receptor (TLR) signaling pathways thereby linking innate immunity and inflammatory responses critical for host defense and disease progression.
CD68 is associated with atherosclerosis and multiple sclerosis. In atherosclerosis its role becomes evident as it accumulates in macrophages within the plaques making it a marker of disease severity. In multiple sclerosis CD68 expression in macrophages and microglia indicates active demyelination and inflammation. It also relates to proteins such as CD36 in atherosclerosis where both mediate the uptake of modified LDL contributing to foam cell formation in plaques.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Flow cytometric analysis of Raji (human Burkitt's lymphoma cell line) cells labeling CD68 with ab192847 at 1/100 dilution (green) compared with a negative control rabbit IgG (blue).
CD68 immunohistochemistry staining of human tonsil using rabbit anti-CD68 antibody
Fluorescence multiplex immunohistochemical analysis of normal human tonsil tissue (formalin-fixed paraffin-embedded section).
Merged staining of anti-PD1 (Anti-PD1 antibody [CAL20] ab237728; orange; Opal™520) anti-PDL1 (Anti-PD-L1 antibody [CAL10] ab237726; green; Opal™540) anti-CD68 (ab192847; yellow; Opal™570) anti-CD3 epsilon (Anti-CD3 epsilon antibody [SP7] ab16669; red; Opal™620) anti-Ki67 (Anti-Ki67 antibody [SP6] ab16667; light blue; Opal™650) and anti-PanCK (Anti-pan Cytokeratin antibody [C-11] ab7753; grey; Opal™690).
The immunostaining was performed on a Leica Biosystems BOND® RX instrument with an Opal™ 7-color automation IHC kit (NEL821001KT Akoya Biosciences®).
The section was incubated in six rounds of staining; in the order of Anti-PD1 antibody [CAL20] ab237728 (1/500 dilution), Anti-PD-L1 antibody [CAL10] ab237726 (1/500 dilution), ab192847 (1/300 dilution), Anti-CD3 epsilon antibody [SP7] ab16669 (1/300 dilution), Anti-Ki67 antibody [SP6] ab16667 (1/200 dilution) and Anti-pan Cytokeratin antibody [C-11] ab7753 (1/200 dilution); each using a separate fluorescent tyramide signal amplification system.
Sodium citrate antigen retrieval (Leica ER1 pH6.0 30 minutes) was used in between rounds of tyramide signal amplification to remove the antibody from the previous round to avoid any cross-reactivity.
DAPI (dark blue) was used as a nuclear counter stain.
Microscopy and pseudocoloring of individual Opal™ dyes was performed using a Vectra Polaris.
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human tonsil tissue sections labeling CD68 with ab192847 at 1/100 dilution (0.184 μg/ml) (incubated for 10 minutes at room temperature). Heat mediated antigen retrieval was performed with sodium citrate buffer (pH 6.0, epitope retrieval solution 1) for 20 minutes. Goat Anti-Rabbit & Mouse IgG (HRP) was used as the secondary antibody. Hematoxylin was used as a counterstain. Negative control: PBS instead of the primary antibody.
Positive staining on the macrophages in human tonsil, performed on a Leica Biosystems BOND® RX instrument.
Formalin-fixed, paraffin-embedded human tonsil tissue stained for CD68 using ab192847 at 1/100 dilution in immunohistochemical analysis.
10-color fluorescence multiplex immunohistochemical analysis of human lung cancer tissue (formalin-fixed paraffin-embedded section).
Merged and separate images on the staining of anti-FOXP3 (Anti-FOXP3 antibody [EPR22102-37] ab215206), anti-PD1 (Anti-PD1 antibody [NAT105] ab52587), anti-CD163 (Anti-CD163 antibody [EPR19518] ab182422), anti-HLA-DR (Anti-HLA-DR antibody [EPR3692] ab92511), anti-CD4 (Anti-CD4 antibody [EPR6855] ab133616), anti-CD8 alpha (Anti-CD8 alpha antibody [SP16] ab101500), anti-CD20 (Anti-CD20 antibody [L26] ab9475), anti-CD68 (ab192847), anti-Cytokeratin 19 (Anti-Cytokeratin 19 antibody [EP1580Y] - Cytoskeleton Marker ab52625). Nuclear counter stain shown in dark blue.
The section was incubated in nine rounds of staining; in the order of Anti-FOXP3 antibody [EPR22102-37] ab215206 (1/100 dilution), Anti-PD1 antibody [NAT105] ab52587 (1/200 dilution), Anti-CD163 antibody [EPR19518] ab182422 (1/300 dilution), Anti-HLA-DR antibody [EPR3692] ab92511 (1/200 dilution), Anti-CD4 antibody [EPR6855] ab133616 (1/600 dilution), Anti-CD8 alpha antibody [SP16] ab101500 (1/300 dilution), Anti-CD20 antibody [L26] ab9475 (1/100 dilution), ab192847 (1/300 dilution), Anti-Cytokeratin 19 antibody [EP1580Y] - Cytoskeleton Marker ab52625 (1/400 dilution); each using a separate fluorescent tyramide signal amplification system.
Sodium citrate antigen retrieval (pH6.0) was used in between rounds of tyramide signal amplification to remove the antibody from the previous round, to avoid any cross-reactivity.
Image acquisition was performed with TissueFAXS Spectra (TissueGnostics).
10-color fluorescence multiplex immunohistochemical analysis of human lung cancer tissue (formalin-fixed paraffin-embedded section).
Merged staining of anti-FOXP3 (Anti-FOXP3 antibody [EPR22102-37] ab215206; Cyan; TG540N), anti-PD1 (Anti-PD1 antibody [NAT105] ab52587; Violet; TG700N), anti-CD163 (Anti-CD163 antibody [EPR19518] ab182422; Red; TG650N), anti-HLA-DR (Anti-HLA-DR antibody [EPR3692] ab92511; Yellow; TG570N), anti-CD4 (Anti-CD4 antibody [EPR6855] ab133616; Orange; TG620N), anti-CD8 alpha (Anti-CD8 alpha antibody [SP16] ab101500; Purple; TG540S), anti-CD20 (Anti-CD20 antibody [L26] ab9475; Grey; TG660S), anti-CD68 (ab192847; Green; TG520N), anti-Cytokeratin 19 (Anti-Cytokeratin 19 antibody [EP1580Y] - Cytoskeleton Marker ab52625; Light blue; TG440N). TG470SN (dark blue) was used as a nuclear counter stain.
The section was incubated in nine rounds of staining; in the order of Anti-FOXP3 antibody [EPR22102-37] ab215206 (1/100 dilution), Anti-PD1 antibody [NAT105] ab52587 (1/200 dilution), Anti-CD163 antibody [EPR19518] ab182422 (1/300 dilution), Anti-HLA-DR antibody [EPR3692] ab92511 (1/200 dilution), Anti-CD4 antibody [EPR6855] ab133616 (1/600 dilution), Anti-CD8 alpha antibody [SP16] ab101500 (1/300 dilution), Anti-CD20 antibody [L26] ab9475 (1/100 dilution), ab192847 (1/300 dilution), Anti-Cytokeratin 19 antibody [EP1580Y] - Cytoskeleton Marker ab52625 (1/400 dilution); each using a separate fluorescent tyramide signal amplification system.
Sodium citrate antigen retrieval (pH6.0) was used in between rounds of tyramide signal amplification to remove the antibody from the previous round, to avoid any cross-reactivity.
Image acquisition was performed with TissueFAXS Spectra (TissueGnostics).
Immunohistochemical analysis of formalin fixed paraffin (FFPE) embedded tonsil labelling CD68 with ab192847 at a dilution of 1/600. The immunostaining was performed on a Ventana DISCOVERY ULTRA (Roche Tissue Diagnostics) instrument with an ChromoMap DAB (RUO) IHC Detection Kit with anti rabbit HQ and anti HQ HRP. Heat mediated antigen retrieval was conducted for 24 min with DISCOVERY cell conditioning solution (CC1) 100°C, pH 8.5. ab192847 was incubated at 37°C for 16 min. Sections were counterstained is with Hematoxylin II. Image inset shows absence of staining in secondary antibody only control.
CD68 immunohistochemistry staining of human tonsil using rabbit anti-CD68 antibody
Chromogenic multiplex immunohistochemical staining of FFPE normal human tonsil tissue. Anti-Ki67 antibody [SP6] ab16667 anti-Ki67 DAB chromogen. Anti-CD3 epsilon antibody [SP7] ab16669 anti-CD3 epsilon purple chromogen and ab192847 anti-CD68 teal chromogen plus haematoxylin II counterstain. Chromogenic immunostaining was performed on a Roche Ventana Benchmark Ultra instrument. The section was deparaffinised and incubated with CC1 solution for 24min 100oC. Following this with 3 rounds of staining in the order of Anti-Ki67 antibody [SP6] ab16667 (1/500 dilution), ab192847 (1/4000 dilution) and Anti-CD3 epsilon antibody [SP7] ab16669 (1/1000 dilution). Between rounds of staining antibody denaturation was conducted using Ultra CC2 solution for 8min at 100oC to avoid cross reactivity. Signal was developed with anti-rabbit HQ followed by anti-HQ HRP coupled with Chromomap DAB kit Discovery purple or Discovery teal chromogens and haematoxylin II counterstain.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com